CD274 and neoplasm: Other new studies are ongoing: in a phase II trial (NCT04396535) (Table 2) docetaxel is administered with or without bintrafusp alfa in treating patients after progressing on a combination of anti-PD-1/PD-L1 and chemotherapy; in a phase III trial (NCT03631706) the efficacy of bintrafusp alfa will be compared with pembrolizumab in patients with high PD-L1-tumor expression and no genetic alterations.